Atar D, Vandenbriele C, Agewall S, Gigante B, Goette A, Gorog DA, Holme PA, Krychtiuk KA, Rocca B, Siller-Matula JM, Valgimigli M, Rubboli A, Klamroth R(2025) Management of patients with congenital bleeding disorders and cardiac indications for antithrombotic therapy Eur Heart J Cardiovasc Pharmacother(in press) DOI 10.1093/ehjcvp/pvaf006, PubMed 40145128
Måseide RJ, Berntorp E, Astermark J, Olsson A, Bruzelius M, Frisk T, Nummi V, Lassila R, Strandberg K, Tjønnfjord GE, Holme PA(2024) Nonneutralizing antibodies in Nordic persons with moderate hemophilia A and B (the MoHem study) Res Pract Thromb Haemost, 8(8), 102611 DOI 10.1016/j.rpth.2024.102611, PubMed 39807249
Reding MT, Lalezari S, Kenet G, Di Minno G, Ducore J, Solms A, Shah A, Holme PA, Poulsen LH, Meijer K, Simpson M, Mancuso ME(2024) Correction: Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review Drugs R D, 25(1), 89-98 DOI 10.1007/s40268-024-00494-2, PubMed 39702563
